IMAGE: Charles J. Dimitroff, PhD, left, helps to train the next generation of immune/cancer research scientists. His laboratory is focused on the glyco-pathological basis of immunity, inflammation and cancer. view more
Credit: Charles Dimitroff, Brigham and Women’s Hospital
Two new studies have unveiled how a peculiar molecule impacts how antibody-producing cells develop and function as well as how normal melanocytes progress to melanoma malignancy.
“These findings on fundamental immunology and melanoma development originate from totally different areas of research, though have intersected at the bench,” said Charles Dimitroff, PhD, of the Department of Dermatology at Brigham and Women’s Hospital.
The Dimitroff lab, along with collaborators at Imperial College London, recently published two back-to-back-articles in the journal, Nature Communications, detailing novel findings on cell surface carbohydrates (‘glycans’) regulating human B cell function and human melanoma progression – two scientific areas seemingly at the opposite ends of the research spectrum. Over a five-year period in the Dimitroff laboratory, Nicholas Giovannone, PhD, and Jenna Geddes Sweeney, PhD, who were investigating the global glycan features of human B cells at various stages of differentiation and of normal and malignant melanocytes, independently discovered that a distinct glycan feature known as blood group I-antigen or
Article originally posted at